Nosopharm is an innovative biotechnology company specialized in
anti-infective drug discovery.
Our mission is to discover and develop new anti-infective drugs to combat antimicrobial resistance and infectious diseases. Our R&D programs are based on the exploitation of Photorhabdus and Xenorhabdus, two underexplored antimicrobial-producing bacteria on which we based our unique drug discovery platform. Nosopharm is the only biotech company to explore these two high-potential bacteria for anti-infective applications.
Photorhabdus and Xenorhabdus are unique micro-organisms with strong potential for drug discovery in infectious diseases
Nosopharm develops a pipeline of innovative first-in-class anti-infectives against the WHO critical priority pathogens
Meet the seasoned management and scientific team behind Nosopharm’s development & pipeline
An important milestone has been reached for the GNA NOW Consortium with the completion of the GLP toxicology studies for the NOSO-502 program. The results
Collaboration aims to produce chemical libraries of bioactive molecules that will feed into Nosopharm’s anti-infective screening procedures Nosopharm and its partner, the DGIMI laboratory (UMR
Our CEO, Philippe Villain-Guillot @PVG_NOSOPHARM , presented our unique anti-infective drug discovery platform and pipeline yesterday at #BIO2022
[#BIO2022] @Nosopharm is the only #Biotech company to explore the antimicrobial-producing bacteria Photorhabdus and Xenorhabdus for anti-infective applications.
#FrenchHealthcare @IAmBiotech @BIOConvention @BF_HealthcareNA
Subscribe to our newsfeed
Nosopharm is open to synergistic collaborations for the development of its pipeline and the progress of its promising drug discovery programs.
Our goal is to explore, with an industrial partner, the drug discovery potential of Photorhabdus and Xenorhabdus bacteria for human and animal health in any therapeutic indication. Our innovative anti-infective drug discovery platform is based on the exploitation of these two antimicrobial-producing bacteria; Nosopharm is the only biotech company to explore these. Nosopharm is also interested in gaining access to new strains of Photorhabdus and Xenorhabdus or related bacteria, in compliance with the Nagoya Protocol.
To explore partnering opportunities with Nosopharm, please contact us.
Nosopharm is an innovative biotechnology company specialized in exploring the microbial biodiversity of the genera Photorhabdus and Xenorhabdus to develop new drugs infectious diseases.
;